Anything is
Druggable
with Quantum Accuracy
They support us:
Qubit Pharmaceuticals brings unparalleled accuracy and precision to molecular design, using quantum physics and artificial intelligence to develop life-changing treatments for major diseases.
Better treatments
for any target & every patient
Our proprietary technologies, the fruit of over 30 years of continuing research, make it possible to develop novel drug candidates and innovative modes of action against targets previously considered too complex.
Impact
Qubit Pharmaceuticals is achieving the highest accuracy yet in solving Schrödinger's equation, driving advancements across industries.
An expert team
Our founders head world-leading quantum labs in the USA and France. Our 60+ employees have expertise across deep tech and pharma across our offices in Paris, Boston & Chicago.
Data advantage for chemical accuracy
We generate proprietary first principles synthetic data and apply transfer learning across DFT, QMC, sCI and FCI for fast and cost effective data generation.
quantum capabilities for molecular simulation
We've built the world's first quantum-enabled foundation model and platform, unifying Physics, AI, and Quantum for superior performance and scalable applications.
Diversification in other chemical industries
Our technology unlocks the entire chemical space, across industries. It scales across applications by learning the underlying chemistry and physics rules.
Atlas
Quantum, AI and Physics-Inspired Platform for High-Precision Molecular Modeling
Qubit Pharmaceuticals’ ATLAS platform brings together decades of advanced computational chemistry research, refined and integrated since our inception in 2021. ATLAS provides high-precision molecular simulation and modeling as well as molecule generation.
By enabling this level of accuracy, ATLAS reduces the time required to select and optimize a drug candidate by half and decreases the need for experimental validation by at least tenfold.
1000+
nanoseconds
1000ns of MD simulation per day with polarizable force fields
30+
qubits
Hybrid HPC-QC ready for computations over 30 qubits
Behind every target deemed too complex is a real patient with unmet needs.
We are developing novel drugs to cure life-threatening diseases, with a primary focus on oncology, inflammation and pandemic response.
We have multiple fully owned & partnered programs in discovery and are pursuing a broad pipeline of additional targets.
We actively shift the paradigm in drug discovery from drug hunting to drug farming.
Robert Marino, PhD
CEO Qubit Pharmaceuticals
Project pipeline
TARGET / Pathway
therapeutics areas
Target/ MOA characterisation
Hit to lead
Lead to pre-candidate
partner
KAT6A
Oncology
IL4R
Inflammation
RAS/RAF
Oncology
TREX1
Sting Pathway
Undisclosed GPCR
Multiple
RNA Platform (Malat-1, LIN28)
Oncology & Inflammation
Antivirals
Platform
Multiple targets in partnerships
Various
+ 16 additional drug discovery programs under evaluation
Project pipeline
IL4R
Inflammation
Target / MOA
characterisation
Hit to lead
Lead to
pre-candidate
USP7
Oncology
Target / MOA
characterisation
Hit to lead
Lead to
pre-candidate
MRas
Ras driven oncology
Target / MOA
characterisation
Hit to lead
Lead to
pre-candidate
KAT6A
Oncology
Target / MOA
characterisation
Hit to lead
Lead to
pre-candidate
Undisclosed Metalloenzyme
Oncology
Target / MOA
characterisation
Hit to lead
Lead to
pre-candidate
Undisclosed GPCR
Oncology & Inflammation
Target / MOA
characterisation
Hit to lead
Lead to
pre-candidate
+16 additional discovery programs
Various
Various
Target / MOA
characterisation
Hit to lead
Lead to
pre-candidate
supercomputer
drug discovery programs brought to preclinicals and clinical stages by team members during their careers.
PhDs
publications
raised
Meet
our
founders
Expert in High Performance Computing, numerical methods and sampling. Lead developer Tinker-HP. Atos Fourier Prize Laureate.
Expert in drug discovery. 8 patents. 1 program at clinical stage.
Expert in quantum chemistry and High Performance Computional. Atos Fourier Prize and ERC Synergy Laureate. Scientific leader Tinker-HP. Fellow of the Royal Society of Chemistry (London).
Expert in structural biology and biomolecular simulation. Fellow of AAAS and past Gordon conference chairperson. Lead developer Tinker and AMOEBA.
Professor of Biomedical Engineering. Expert in multi-scale modelling of proteins and nucleic acids. Lead developer Amoeba.
One team, one mission, infinite ambition
Based in Paris and Boston, our team of over 60 people is made up of over 18 different nationalities. We are a diverse mix of various expertise, backgrounds and perspectives. Our mission? We pioneer quantum-aided drug discovery and leverage cutting-edge science to design novel molecules for complex targets.
Developing better drugs, together
Drug discovery is very much a team effort. We are always looking to explore ways to develop novel treatments to cure major diseases.
We’re looking for partners to co-develop our drug discovery programs. We’re also keen to evaluate the possibility to jointly accelerate existing drug discovery programs or unlock complex targets with the support of Atlas and our drug discovery team.
We’re interested in expanding our portfolio in inflammation and oncology. We’re seeking for novel targets with ideally a crystal structure available, PDX and/or patient lines available and a lab stage assay. Prior demonstration of druggability is not mandatory.
Interested in partnering with us?
News & Research
May 20, 2025
Press Release
Sorbonne University and Qubit Pharmaceuticals unveil the world's most powerful Quantum AI model to discover new medicines
May 1, 2025
Journal of Physical Chemistry Letters
Research Publication: Lambda-ABF-OPES: Faster Convergence with High Accuracy in Alchemical Free Energy Calculations
%20(1).png)
March 18, 2025
Press Release
Qubit Pharmaceuticals announces the appointment of Robin Chaudret, a renowned expert in molecular modeling, as Chief Technology Officer
.png)
February 18, 2025
Press Release
Qubit Pharmaceuticals selected to join Cité de l'Innovation Sorbonne Université
.png)
January 10, 2025
ArXiv
Preprint: Quantum Speedup for Nonreversible Markov Chains
December 19, 2024
ArXiv
Preprint: Velocity Jumps for Molecular Dynamics
November 29, 2024
Qubit Pharmaceuticals & Argonne National Lab awarded 1.44 Million GPU Hours through INCITE Program!
November 18, 2024
Nature Communications
Published in Nature Communications: Shortcut to chemically accurate quantum computing via density-based basis-set correction
October 24, 2024
Blog
Unlocking RNA Targets: Advancing Drug Discovery with Cutting-Edge Simulations
%20(1).png)
October 11, 2024
ArXiv
Preprint: The velocity jump Langevin process and its splitting scheme: long time convergence and numerical accuracy
.png)
October 7, 2024
Blog
Joint research paper with Pasqal: How Analog Quantum Computing is Transforming Drug Discovery
.png)
September 12, 2024
LinkedIn Blog
Paper on Spike Protein Dynamics among the 2024 Chemical Science HOT Articles Collection
%20(1).png)
August 13, 2024
Press Release
Qubit Pharmaceuticals nominated for "Best Startup 2024" award by Prix Galien USA
July 10, 2024
Press Release
Major breakthrough in quantum algorithms: Qubit Pharma and Sorbonne University drastically reduce the number of qubits needed to simulate molecules
.png)
June 6, 2024
Press Release
Qubit Pharmaceuticals selected as one of the 100 Technology Pioneers 2024 by the World Economic Forum
January 30, 2024
Press Release
High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux Join Forces to Advance the Development of Novel Cancer Therapies
.png)
December 13, 2023
Press Release
Qubit Pharmaceuticals strengthens its commitment to DistriQ - Quantum Innovation Zone by partnering with the PINQ² platform in order to accelerate pharmaceutical research through quantum computing
December 6, 2023
Press Release
Qubit Pharmaceuticals and Sorbonne University achieve a major scientific breakthrough by simulating quantum calculations at more than 40 qubits on conventional computers
.png)
November 16, 2023
Qubit Pharmaceuticals Invests €4.5M in Innovative RNA Therapeutics Platform!
November 9, 2023
Advancing Quantum Chemistry with Quantum Computing: A Pioneering Approach to Sparse Quantum State Preparation for Strongly Correlated Systems
November 7, 2023
Qubit Pharmaceuticals honored to announce the arrival of renowned Quantum Computing researcher Dr. Alberto Peruzzo as R&D Lead in Quantum Computing
September 28, 2023
Revolutionizing Drug Discovery: Quantum Computing Meets Solvent Configuration Prediction
September 26, 2023
French start-ups Pasqal and Qubit Pharmaceuticals join with Unitary Fund to win Wellcome Trust's "Quantum for Bio" program
June 12, 2023
Qubit Pharmaceuticals joins the Acuité Québec Consortium to innovate in drug design
May 22, 2023
"The purpose of Qubit Pharmaceuticals is to treat patients."
May 12, 2023
Qubit Pharmaceuticals is joining the partner ecosystem of Eviden , an Atos business!
March 31, 2023
Qubit Pharmaceuticals is a laureate of the very first class of the French Tech #Health20!
March 14, 2023
Thanks a lot France Digitale and XAnge for identifying us as a future digital champion!
January 24, 2023
A big step forward for quantum computer-assisted #drugdiscovery at Qubit Pharmaceuticals!
November 30, 2022
Nvidia
Qubit Pharmaceuticals Accelerates Drug Discovery With Hybrid Quantum Computing
November 29, 2022
HPC Innovation Excellence Award
November 7, 2022
We are part of Fujitsu Accelerator Program for CaaS !
March 31, 2023
Qubit Pharmaceuticals is a laureate of the very first class of the French Tech #Health20!
©2023 Qubit Pharmaceuticals.
All Rights Reserved.
Disclaimer: Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EISMEA. Neither the European Union nor the granting authority can be held responsible for them.
Legal notice